Physician profile
Leigh Van Devender
NPI 1376198192
$16,270.06
in general payments reported to CMS, 2019-2025
25 companies · $3,230 in 2025
The $3,230 reported for 2025 was more than what 97% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,141 · 2022: $2,659 · 2023: $3,282 · 2024: $3,958 · 2025: $3,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,281.62 |
| Education | $188.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,078.77 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $3,602.38 | 2021-2025 | |
| Janssen Biotech, INC. | $1,343.25 | 2021-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $1,221.03 | 2021-2025 | |
| Ucb, INC. | $1,104.32 | 2021-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $965.78 | 2021-2025 | Ofev, Cyltezo |
| Pfizer INC. | $645.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $637.69 | 2021-2025 | Saphnelo, Enhertu, Flumist Quadrivalent |
| Lilly USA, LLC | $426.76 | 2021-2025 | Taltz, Zepbound |
| Aurinia Pharma U.S., INC. | $376.48 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $376.17 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $304.46 | 2022-2024 | Acthar |
| Fresenius Kabi USA, LLC | $296.73 | 2023-2025 | Idacio, Tyenne |
| Organon LLC | $244.95 | 2024-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $133.07 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $108.49 | 2021-2025 | |
| Genentech USA, INC. | $108.23 | 2021-2025 | Actemra, Gazyva |
| E.R. Squibb & Sons, L.L.C. | $81.34 | 2024-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $57.63 | 2022-2025 | Strensiq |
| Scilex Pharmaceuticals INC. | $45.67 | 2025 | |
| Mylan Institutional INC. | $35.04 | 2023 | Hulio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.71 | 2023 | Xifaxan |
| Hikma Pharmaceuticals USA | $21.11 | 2021 | |
| Almatica Pharma LLC | $17.92 | 2024 | Teriparatide |
| Sobi, INC | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Van Devender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.